SURGICEPT™ Waterless Handwash is Effective Against Viruses
Healthpoint (Fort Worth, Tex) announces that SURGICEPT™ Waterless Surgical Hand Antiseptic, the latest addition to the Healthpoint asepsis product line for healthcare personnel hand washing, kills viruses in addition to fighting bacteria as reported in study results presented during the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy held in San Francisco, Calif, September 27–30, 2006.
The study, “Antiviral Activity of a Novel Waterless Alcohol-Based Surgical Scrub,” discussed how SURGICEPT killed a variety of viral agents. The formulation includes a 70% ethyl alcohol concentration as well as a patented preservative system.
Healthcare workers can spread a variety of viral and bacterial diseases with their hands when performing routine patient care duties. Killing both bacteria and viruses is critical especially regarding nosocomial infections and surgical site infections (SSI).
According to the study, the viruses that succumbed to SURGICEPT included adenovirus, herpes simplex virus type 1 and 2, influenza A virus, rhinovirus, vaccinia virus, bovine viral diarrhea virus, murine leukemia virus, hepatitis A virus, rotavirus, human respiratory syncytial virus, and feline calcivirus virus, as well as the bacterium Clostridium difficile. These represent—directly or as surrogates—disease agents that are responsible for a number of human diseases including some that can be fatal. The results indicated that the treatment frequently destroyed 99% or more of the listed infectious agents.
Although this study only tested virus-killing capacity, SURGICEPT has already been proven to kill bacteria.
Visit http://www.healthpoint.com for more information.
POSiFECT® RD Bioelectric Stimulation Therapy Product Receives Marketing Clearance Biofisica LLC (Atlanta, Ga) announces that the company has received clearance to market POSiFECT® RD Bioelectric Stimulation Therapy. Biofisica worked with the British Standards Institute (BSI) throughout the conformity assessment process and has received clearance to affix the European CE Mark to its product.
The company now plans to launch the product in the UK followed by staged rollouts in France, Germany, and the Nordic region. This is the first device available that combines 2 technologies—moist wound care dressing and electrical stimulation—in a disposable, easy-to-use, sterile dressing that facilitates the normal healing process. Early clinical research has shown healing in many difficult to heal or nonhealing wounds.
Bioelectric stimulation therapy is indicated for the management of chronic wounds where conventional therapies have failed. It is designed for use on chronic wounds including venous leg ulcers, pressure ulcers, and diabetic foot ulcers. The dressing contains a miniature electrical circuit that delivers a microcurrent to the wound bed. Nonrechargeable coin cell batteries power the microcurrent. The dressing remains on the wound for 48 hours and is then replaced with a new dressing.
Visit http://www.biofisica.com for more information.
Bandage for Hard-To-Heal Wounds Now Available in the US The Bauer Bandage (St. Rita Medical, LLC, Houston, Tex) was developed in European medical centers over the last 5 years. The bandage has shown success in healing wounds faster and providing patient comfort. It also has shown other important properties such as low wound surface adherence and effective deodorization.
The new bandage has proven successful for healing diabetic, venous, and decubitus ulcers, pressure ulcers, burns, infected surface wounds, operative wounds, surface traumas, and other conditions and defects.
The bandage contains a special form of carbon. The pure, activated carbon is in textile form and is pliable, flexible, and conforming. The carbon is tightly woven and acts as an absorptive covering.
The microscopic fibers of activated carbon provide absorptive capacity and speed up the wound healing process significantly in most observed cases. The high absorption rate slows or stops the growth of infectious microbial activity of many kinds and allows the tissues to regenerate more quickly.
The company is currently developing distribution channels for the bandage in the US market.
For more information, visit http://www.bauerbandageusa.com or call (281) 451-4222.
New Bari 10-A™ Bed Frame Meets FDA Safety Guidelines and Promotes Caregiver and Patient Safety TriLine Medical (Van Nuys, Calif) now offers a true 1,000 lb bariatric bed that meets the newest US Food and Drug Administration (FDA) patient and caregiver safety guidelines while addressing the growing need for an affordable, quality solution to meet the special challenges of the bariatric patient population that is estimated to be more than 60 million Americans.
The Bari 10-A™ is designed to assist hospitals with this challenge. The Bari 10-A™ is equipped with many features that provide the bariatric patient and their caregivers with safety, flexibility, comfort, and security. The bed features an integrated electronic bed scale conveniently allows patient to be weighed while in the bed, a battery back up that provides power in the event of power outage or during patient transfer, and optional CairRails™ side air bolsters that prevent entrapment and provide the caregiver easy access for patient care when a pressure mattress is ordered with the frame.
The bariatric bed is safe, effective, flexible, durable, cost-effective and one the safest, most affordable quality bariatric bed frames available in the healthcare industry.
TriLine will bring the bed to your facility so that you can evaluate it prior to purchase or rental.
Call (800) 966-6662 or e-mail info@trilinemedical.com for more information.
Pegasus Biologics Enters Wound Care Market with FDA Clearance for DermADAPT™ Biomatrix Pegasus Biologics (Irvine, Calif) announces the company has received US Food and Drug Administration (FDA) clearance for the DermADAPT™ Biomatrix Wound Dressing, a highly organized, collagen matrix intended for the local management of moderate to heavy exuding wounds.
The company will initially focus on the diabetic foot ulcer market.
The FDA clearance allows the company to market the DermADAPT Biomatrix for the management of a variety of wounds including pressure ulcers, venous ulcers, surgical, podiatric, and trauma wounds, including partial-thickness burns.
The DermADAPT Biomatrix and the OrthADAPT Bioimplants utilize Pegasus Biologics’ proprietary licensed technologies, UltiFIX® and UltiSTER™, that stabilize and sterilize biological tissues using safe and nondestructive methods, resulting in decellularized collagen matrices that are biocompatible and strong. Studies have indicated that these scaffolds are resistant to enzymes for controlled biodegradation and subsequent remodeling in the patient.
Visit http://www.pegasusbio.com for more information.
|
